Eczematous Adverse Drug Reaction After Selpercatinib Treatment
Author Information
Author(s): Li Bingrun, Cao Peng, Xu Wenjing, Zhang Litao
Primary Institution: Tianjin University of Traditional Chinese Medicine
Hypothesis
What is the incidence and clinical management of selpercatinib-induced cutaneous eczematous reactions?
Conclusion
The study provides novel evidence for the treatment of selpercatinib-induced cutaneous eczematous reactions.
Supporting Evidence
- The patient developed eczematous skin lesions after 4 weeks of selpercatinib treatment.
- Glucocorticoid treatment led to significant improvement in the patient's skin condition.
- This is the first report of cutaneous toxicities associated with selpercatinib treatment.
Takeaway
A 50-year-old patient developed a skin rash after taking a cancer drug called selpercatinib, but treatment helped improve the rash.
Methodology
The patient was treated with glucocorticoids and topical creams after developing eczematous skin lesions.
Limitations
The study is based on a single case report, limiting the generalizability of the findings.
Participant Demographics
One 50-year-old patient with non-small cell lung cancer and a secondary malignant tumor.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website